Clinical trials: Metabolism and Excretion
Healthy Volunteers
Study to Evaluate Absorption, Metabolism, and Excretion, of TAK-994 in 6 Healthy Male Adults
The aim of this study is to understand how TAK-994 is processed by the body. This study will require participants to stay at the clinical research unit for 3 weeks to be monitored after receiving TAK-994.
- Trial name
- NCT04833049
- Testing
- TAK-994 Oral Tablet, [14C]TAK-994 Intravenous Infusion, [14C]TAK-994 Oral Suspension
- Where
- United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Takeda
Chronic Kidney Disease Patients
Metabolism and Excretory of HSK21542 in Maintenance Hemodialysis Patients
This is a single-center, nonrandomized, and open design study to investigate metabolism and excretion of HSK21542 in maintenance hemodialysis patients.
- Trial name
- NCT06238388
- Testing
- HSK21542 Injection
- Where
- China
- Volunteers
- 6 people
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
Healthy Subjects
The Acute Effect of Atorvastain on Renal Function in Patients With Type II Diabetes
We wanted to test the hypothesis that acute treatment with atorvastatin changes renal sodium excretion, glomerular filtration rate, tubular function and vasoactive hormones in patients with type II diabetes, not in treatment with…
- Trial name
- NCT00678522
- Testing
- Atorvastatin
- Where
- 2 sites in Denmark
- Volunteers
- 25 people
- Sponsor
- Regional Hospital Holstebro
Healthy
Phase I Study to Determine the Absorption, Distribution, Metabolism and Excretion of Esreboxetine
The purpose of the study is to learn more about how esreboxetine is handled by the body i.e. the absorption, metabolism and excretion of esreboxetine.
- Trial name
- ADME (NCT00800956)
- Testing
- [14C]-esreboxetine
- Where
- United States
- Volunteers
- 4 people, healthy volunteers welcome
- Sponsor
- Pfizer
Healthy
A Study of [14C]-LY4065967 in Healthy Participants
The purpose of this study is to investigate the absorption, metabolism, excretion, and bioavailability of LY4065967 in healthy male participants. This is a 2-part study.
- Trial name
- NCT07039045
- Testing
- LY4065967, [14C]-LY4065967 Oral, [14C]-LY4065967 IV
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Obesity
Effect of Milk and Cheese on Fecal Fat Excretion and Blood Lipid
The aim is to study the effect of milk versus cheese on fecal fat excretion and blood lipids. To do this, a randomized crossover intervention study with 3 14-day periods (control diet, milk diet, cheese diet) will be conducted in…
- Trial name
- MOFF (NCT01317251)
- Testing
- Dietary intervention (without dairy products), Dietary intervention (high milk content), Dietary intervention (high cheese content)
- Where
- Denmark
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- University of Copenhagen
Healthy Volunteers
A Study to Evaluate the Absorption, Metabolism, and Excretion of [14C]BMS-986419 in Healthy Male Participants
The purpose of this study is to assess the pharmacokinetics (PK), metabolite profile, routes and extent of elimination, mass balance, as well as safety and tolerability of [14C]BMS-986419 in healthy male participants.
- Trial name
- NCT05847439
- Testing
- [14C]BMS-986419
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Nocturnal Enuresis, Vitamin D Deficiency
Vitamin D Versus Desmopressin Versus Combination Therapy in Children With Primary Monosymptomatic Nocturnal Enuresis and Vitamin D Deficiency
This randomized clinical trial evaluated three treatment approaches for children aged 6 to 12 years who had primary monosymptomatic nocturnal enuresis (night-time bedwetting) and confirmed vitamin D deficiency.
- Trial name
- NCT07292753
- Testing
- Vitamin D, Desmopressin
- Where
- Egypt
- Volunteers
- 90 people
- Sponsor
- Ain Shams University
Coronary Artery Disease
Study of [3H] BMS747158 in Healthy Male Subjects
The purpose of this clinical study is to assess the safety, extent and route of [3H] BMS747158 radioactivity eliminated (mass balance) in urine and feces of healthy male subjects.
- Trial name
- PPA103 (NCT00930631)
- Testing
- [3H] BMS747158
- Where
- United States
- Volunteers
- 7 people, healthy volunteers welcome
- Sponsor
- Lantheus Medical Imaging
Healthy
Single-dose Study of [14C]PF-05221304 Metabolism and Excretion in Healthy Adult Male Subjects
The purpose of the study is to characterize the absorption, distribution, metabolism, and excretion (ADME) of a single oral dose of [14C]PF-05221304 in Healthy Adult Male Subjects
- Trial name
- NCT03448172
- Testing
- [14C]PF-05221304
- Where
- United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Pfizer
Major Depressive Disorder
Study to Assess the Distribution, Metabolism and Excretion of [14C]AZD6765 After a Single-Dose Intravenous Administration
This is a study to assess the distribution, metabolism and excretion of [14C]AZD6765 after a single-dose intravenous administration.
- Trial name
- AZD6765 (NCT01217645)
- Testing
- 150 mg [14C] AZD6765
- Where
- United Kingdom
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Healthy
Study of the Absorption, Metabolism, and Excretion Following a Single Dose of [14C]-Poziotinib in Healthy Male Subjects
This will be a Phase 1, open-label, nonrandomized, single-dose study in healthy male subjects to evaluate the Absorption, Metabolism, and Excretion of Poziotinib following a single oral dose of [14C]-poziotinib to healthy male…
- Trial name
- NCT04436562
- Testing
- [14C]-Poziotinib
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Spectrum Pharmaceuticals, Inc
Neuroscience
Study Evaluating Absorption, Distribution, Metabolism and Excretion (ADME) of Single Dose [14C] AZD2423 in Volunteers
Phase I study to evaluate the excretion of radioactivity, the metabolic profile, pharmacokinetics, safety and tolerability following a single oral administration of [14C]AZD2423 in healthy male volunteers aged 50 to 65 years…
- Trial name
- ADME (NCT01223014)
- Testing
- AZD2423
- Where
- United Kingdom
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Asthma
An ADME Study of [14C]AZD4604 and the Absolute Bioavailability of AZD4604
The Sponsor is developing the test medicine, AZD4604, as a potential treatment for asthma. Asthma is a common lung condition caused by inflammation (swelling) of the breathing tubes that carry air in and out of the lungs, causing…
- Trial name
- NCT06157255
- Testing
- AZD4604 Inhalation Powder, 1 mg, [14C]AZD4604 Solution for Infusion 6 μg/mL (NMT 37.0 kBq/5 mL), [14C]AZD4604 Oral Solution, 4 mg (NMT 37.0 kBq)
- Where
- United Kingdom
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Healthy Adult Male Volunteers
ADME Study of [14C]- Rongliflozin in Healthy Male Subjects
Study to Evaluate the Mass Balance and Biotransformation of Single Dose [14C]- Rongliflozin in healthy male subjects.
- Trial name
- NCT05109078
- Testing
- [14C]- Rongliflozin
- Where
- China
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Sunshine Lake Pharma Co., Ltd.
Coronary Heart Disease, Cardiovascular Disease
Physiological Study of Human Cholesterol Metabolism and Excretion
The underlying hypothesis is that whole body cholesterol - including cholesterol present in tissues that cannot be measured by standard blood tests - is related to heart disease risk.
- Conditions
- Coronary Heart Disease, Cardiovascular Disease, Dyslipidemia, Disorder of Cholesterol Metabolism
- Trial name
- NCT01603758
- Testing
- Ezetimibe
- Where
- United States
- Volunteers
- 132 people, healthy volunteers welcome
- Sponsor
- Richard E. Ostlund Jr., MD
Healthy
A Study of [14C]-LY3866288 in Healthy Participants
The main purpose of this study is to evaluate how much of the study drug (LY3866288), administered as a single dose that has the radioactive substance 14C incorporated into it, passes from blood into urine, feces and expired air…
- Trial name
- NCT06644378
- Testing
- [14C]-LY3866288, LY3866288
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Epilepsy, Seizures
Determination of Absorption and Elimination of Lamotrigine-XR
People over 65 years of ag break down (metabolize) drugs differently than younger adults. It is not known why this happens or how elderly people absorb or break down these drug differently.
- Conditions
- Epilepsy, Seizures, Bipolar Disorder, Bipolar Depression
- Trial name
- NCT00789113
- Testing
- Extended Release Lamotrigine
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of Minnesota
Relapsing-remitting Multiple Sclerosis
Mass Balance Study of MT-1303
The purpose of this study is to investigate the absorption, metabolism and excretion of MT-1303 in healthy subjects.
- Trial name
- NCT02293967
- Testing
- MT-1303
- Where
- United Kingdom
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Tanabe Pharma Corporation
Cardiovascular Diseases
Absorption, Distribution, Metabolism and Excretion of [14C] Labelled BIA 5-1058
The purpose of the study is to determine the mass balance recovery in expired air, urine and faeces after a single oral dose of 400 mg 14C-labeled BIA 5-1058; to provide plasma, urine and faecal samples for metabolite profiling…
- Trial name
- NCT04069130
- Testing
- 400 mg of BIA 5-1058
- Where
- United Kingdom
- Volunteers
- 7 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.